These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 34353882)

  • 1. Pharmacological Characterization of the Imipridone Anticancer Drug ONC201 Reveals a Negative Allosteric Mechanism of Action at the D
    Free RB; Cuoco CA; Xie B; Namkung Y; Prabhu VV; Willette BKA; Day MM; Sanchez-Soto M; Lane JR; Laporte SA; Shi L; Allen JE; Sibley DR
    Mol Pharmacol; 2021 Oct; 100(4):372-387. PubMed ID: 34353882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Dopamine Receptors in the Anticancer Activity of ONC201.
    Kline CLB; Ralff MD; Lulla AR; Wagner JM; Abbosh PH; Dicker DT; Allen JE; El-Deiry WS
    Neoplasia; 2018 Jan; 20(1):80-91. PubMed ID: 29216597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism.
    Prabhu VV; Madhukar NS; Gilvary C; Kline CLB; Oster S; El-Deiry WS; Elemento O; Doherty F; VanEngelenburg A; Durrant J; Tarapore RS; Deacon S; Charter N; Jung J; Park DM; Gilbert MR; Rusert J; Wechsler-Reya R; Arrillaga-Romany I; Batchelor TT; Wen PY; Oster W; Allen JE
    Clin Cancer Res; 2019 Apr; 25(7):2305-2313. PubMed ID: 30559168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The action of a negative allosteric modulator at the dopamine D
    Draper-Joyce CJ; Verma RK; Michino M; Shonberg J; Kopinathan A; Klein Herenbrink C; Scammells PJ; Capuano B; Abramyan AM; Thal DM; Javitch JA; Christopoulos A; Shi L; Lane JR
    Sci Rep; 2018 Jan; 8(1):1208. PubMed ID: 29352161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allosteric interactions between agonists and antagonists within the adenosine A2A receptor-dopamine D2 receptor heterotetramer.
    Bonaventura J; Navarro G; Casadó-Anguera V; Azdad K; Rea W; Moreno E; Brugarolas M; Mallol J; Canela EI; Lluís C; Cortés A; Volkow ND; Schiffmann SN; Ferré S; Casadó V
    Proc Natl Acad Sci U S A; 2015 Jul; 112(27):E3609-18. PubMed ID: 26100888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The structural determinants of the bitopic binding mode of a negative allosteric modulator of the dopamine D
    Draper-Joyce CJ; Michino M; Verma RK; Klein Herenbrink C; Shonberg J; Kopinathan A; Scammells PJ; Capuano B; Thal DM; Javitch JA; Christopoulos A; Shi L; Lane JR
    Biochem Pharmacol; 2018 Feb; 148():315-328. PubMed ID: 29325769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ONC201 and imipridones: Anti-cancer compounds with clinical efficacy.
    Prabhu VV; Morrow S; Rahman Kawakibi A; Zhou L; Ralff M; Ray J; Jhaveri A; Ferrarini I; Lee Y; Parker C; Zhang Y; Borsuk R; Chang WI; Honeyman JN; Tavora F; Carneiro B; Raufi A; Huntington K; Carlsen L; Louie A; Safran H; Seyhan AA; Tarapore RS; Schalop L; Stogniew M; Allen JE; Oster W; El-Deiry WS
    Neoplasia; 2020 Dec; 22(12):725-744. PubMed ID: 33142238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ONC201 induces the unfolded protein response (UPR) in high- and low-grade ovarian carcinoma cell lines and leads to cell death regardless of platinum sensitivity.
    Rumman M; Buck S; Polin L; Dzinic S; Boerner J; Winer IS
    Cancer Med; 2021 May; 10(10):3373-3387. PubMed ID: 33932119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multivalent approaches and beyond: novel tools for the investigation of dopamine D2 receptor pharmacology.
    Kopinathan A; Scammells PJ; Lane JR; Capuano B
    Future Med Chem; 2016 Jul; 8(11):1349-72. PubMed ID: 27357619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopamine D3/D2 Receptor Antagonist PF-4363467 Attenuates Opioid Drug-Seeking Behavior without Concomitant D2 Side Effects.
    Wager TT; Chappie T; Horton D; Chandrasekaran RY; Samas B; Dunn-Sims ER; Hsu C; Nawreen N; Vanase-Frawley MA; O'Connor RE; Schmidt CJ; Dlugolenski K; Stratman NC; Majchrzak MJ; Kormos BL; Nguyen DP; Sawant-Basak A; Mead AN
    ACS Chem Neurosci; 2017 Jan; 8(1):165-177. PubMed ID: 27715007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Thieno[2,3- d]pyrimidine Scaffold Is a Novel Negative Allosteric Modulator of the Dopamine D
    Fyfe TJ; Zarzycka B; Lim HD; Kellam B; Mistry SN; Katrich V; Scammells PJ; Lane JR; Capuano B
    J Med Chem; 2019 Jan; 62(1):174-206. PubMed ID: 29683325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical Evaluation of the Effects of Trazpiroben (TAK-906), a Novel, Potent Dopamine D
    Whiting RL; Choppin A; Luehr G; Jasper JR
    J Pharmacol Exp Ther; 2021 Oct; 379(1):85-95. PubMed ID: 34253646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic and inflammatory reprogramming of macrophages by ONC201 translates in a pro-inflammatory environment even in presence of glioblastoma cells.
    Geiß C; Witzler C; Poschet G; Ruf W; Régnier-Vigouroux A
    Eur J Immunol; 2021 May; 51(5):1246-1261. PubMed ID: 33442873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In Vitro and In Vivo Identification of Novel Positive Allosteric Modulators of the Human Dopamine D2 and D3 Receptor.
    Wood M; Ates A; Andre VM; Michel A; Barnaby R; Gillard M
    Mol Pharmacol; 2016 Feb; 89(2):303-12. PubMed ID: 26655303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and structure-activity relationship studies of a series of [4-(4-carboxamidobutyl)]-1-arylpiperazines: insights into structural features contributing to dopamine D3 versus D2 receptor subtype selectivity.
    Ananthan S; Saini SK; Zhou G; Hobrath JV; Padmalayam I; Zhai L; Bostwick JR; Antonio T; Reith ME; McDowell S; Cho E; McAleer L; Taylor M; Luedtke RR
    J Med Chem; 2014 Aug; 57(16):7042-60. PubMed ID: 25126833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-activity study of N-((trans)-4-(2-(7-cyano-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)cyclohexyl)-1H-indole-2-carboxamide (SB269652), a bitopic ligand that acts as a negative allosteric modulator of the dopamine D2 receptor.
    Shonberg J; Draper-Joyce C; Mistry SN; Christopoulos A; Scammells PJ; Lane JR; Capuano B
    J Med Chem; 2015 Jul; 58(13):5287-307. PubMed ID: 26052807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chirality of Novel Bitopic Agonists Determines Unique Pharmacology at the Dopamine D3 Receptor.
    Adhikari P; Xie B; Semeano A; Bonifazi A; Battiti FO; Newman AH; Yano H; Shi L
    Biomolecules; 2021 Apr; 11(4):. PubMed ID: 33924613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinctive binding properties of the negative allosteric modulator, [
    Fasciani I; Pietrantoni I; Rossi M; Mannoury la Cour C; Aloisi G; Marampon F; Scarselli M; Millan MJ; Maggio R
    Eur J Pharmacol; 2018 Jan; 819():181-189. PubMed ID: 29223348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-Kinetic Profiling of Haloperidol Analogues at the Human Dopamine D
    Fyfe TJ; Kellam B; Sykes DA; Capuano B; Scammells PJ; Lane JR; Charlton SJ; Mistry SN
    J Med Chem; 2019 Nov; 62(21):9488-9520. PubMed ID: 31580666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional Characterization of a Novel Series of Biased Signaling Dopamine D3 Receptor Agonists.
    Xu W; Wang X; Tocker AM; Huang P; Reith ME; Liu-Chen LY; Smith AB; Kortagere S
    ACS Chem Neurosci; 2017 Mar; 8(3):486-500. PubMed ID: 27801563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.